YolTech Reports Positive Interim Data on YOLT-202
Single dose of YOLT-202 led to rapid, robust and dose-dependent increases in AAT levels to normal range Single dose of YOLT-202 was well tolerated with...
Category : Clinical Research, Pharma & Healthcare Financing
Ten63 Therapeutics Raises $45M to Advance AI Drug Discovery
— Chugai Venture Fund and the Gates Foundation join new wave of institutional backing for breakthrough BEYOND discovery platform — — BEYOND, an AI-driven drug...
Merlin CP-GEP First GEP Test Recommended by NCCN Melanoma
SkylineDx today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice Guidelines in Oncology for Cutaneous Melanoma (Version 1.2026), recognizing Merlin...
Hope For The Warriors Receives $3M Grant from Lilly Endowment
$3 million investment strengthens foundation for the next generation of military family support Hope For The Warriors (HOPE) has received a $3,000,000 grant from Lilly Endowment...
Flashpoint Publishes Study on Novel HPV Cancer Vaccine
Study in Science Advances shows proprietary Spherical Nucleic Acid (SNA) vaccine platform slows tumor growth and extends survival in preclinical models of HPV-related cancer Flashpoint...
Korsana Biosciences Raises $175M for Neurodegenerative Drugs
Lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s disease KRSA-028 preclinical data support potential for a...
Newron Secures EUR 38M for Phase III Evenamide
Ad hoc announcement pursuant to Art. 53 LR Proceeds expected to fund global ENIGMA-TRS studies and extend cash runway beyond pivotal 12-week results, supporting development...
HYD LLC Confirms 30-Year Cancer Gene Research on Deuterium
A newly published scientific paper titled “Gene Expression Patterns in Lung Adenocarcinoma Cells in Response to Changes in Deuterium Concentration” (Csonka, G.I.; Papp, A.; Somlyai, I.;...
CStone Gets FDA Clearance for CS2009 Phase II Trial
CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial in patients...
HanchorBio Gets FDA Orphan Drug Status for HCB101
First SIRPα-IgG4 Fc Fusion Protein Granted Orphan Status in Gastric Cancer HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology...
EXO 001 Platform Enables In Vivo Multi-Target CAR-T Therapy
Jointly developed by China Medical University Hospital and Ever Supreme Bio Technology, the platform demonstrates compelling preclinical tumor clearance across multiple models Cancer has long...
Agilent Gets FDA Approval for PD-L1 Test in Ovarian Cancer
Approval expands PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab)1, 2 Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration...
ICON Updates Timing of Q4 & Full Year 2025 Earnings Report
Investigation’s preliminary indications are that 2023 and 2024 revenue may have been overstated by less than 2% for each fiscal year ICON plc, (NASDAQ: ICLR)...
Akeso’s IL-4Rα/ST2 Antibody Cleared for Seven Phase II Trials
Akeso, Inc. (9926.HK) is pleased to announce that the National Medical Products Administration has approved the initiation of Phase II clinical trials for AK139, a...
Co-Diagnostics to Showcase PCR Platform at World Health Expo Labs Dubai
Co-Diagnostics, Inc. (OTC: CODX) (“Co-Dx” or “the Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that...